New treatments look to ambush the old in some of pharma's key drug classes

It has been a whirlwind of a year for pharma, with pricing battles, regulatory showdowns and all-but-legendary M&A. But on the ground, it's Rock-em-Sock-em Robots in some of the industry's biggest markets. A steady flow of new drugs in 2014--and a slate of anticipated launches in 2015--have established brands defending their titles and newcomers looking to land a gut-punch or two, if not a knockout. Check out FiercePharma's match-ups to watch in the coming year. Report

Suggested Articles

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Lions Health shared what worked, what campaigns they wish they had created and what they’ll take back home to talk about with their colleagues.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.